Skip to main content
. 2015 Sep 4;10(9):e0137313. doi: 10.1371/journal.pone.0137313

Table 1. Susceptibility of iGAS isolates to various antibiotics in Germany from 2003 to 2013.

All isolates were susceptible to penicillin, cefotaxime and vancomycin.

Macrolides 1 Clindamycin Levofloxacin
Year S (n) S (%) I (n) I (%) R (n) R (%) n S (n) S (%) I (n) I (%) R (n) R (%) n S (n) S (%) I (n) I (%) R (n) R (%) n
2003 67 94.4 0 0.0 4 5.6 71 71 100.0 0 0.0 0 0.0 71 69 100.0 0 0.0 0 0.0 69
2004 154 96.9 0 0.0 5 3.1 159 157 98.7 0 0.0 2 1.3 159 159 100.0 0 0.0 0 0.0 159
2005 80 89.9 2 2.2 7 7.9 89 89 100.0 0 0.0 0 0.0 89 89 100.0 0 0.0 0 0.0 89
2006 84 95.5 0 0.0 4 4.5 88 88 100.0 0 0.0 0 0.0 88 88 100.0 0 0.0 0 0.0 88
2007 81 95.3 0 0.0 4 4.7 85 86 100.0 0 0.0 0 0.0 86 86 100.0 0 0.0 0 0.0 86
2008 104 97.2 0 0.0 3 2.8 107 107 100.0 0 0.0 0 0.0 107 107 100.0 0 0.0 0 0.0 107
2009 112 96.6 0 0.0 4 3.4 116 116 100.0 0 0.0 0 0.0 116 116 100.0 0 0.0 0 0.0 116
2010 127 97.7 0 0.0 3 2.3 130 129 99.2 0 0.0 1 0.8 130 130 100.0 0 0.0 0 0.0 130
2011 115 95.8 0 0.0 5 4.2 120 120 100.0 0 0.0 0 0.0 120 112 93.3 7 5.8 1 0.8 120
2012 129 98.5 0 0.0 2 1.5 131 130 99.2 0 0.0 1 0.8 131 128 97.7 3 2.3 0 0.0 131
2013 161 95.3 0 0.0 8 4.7 169 164 97.0 0 0.0 5 3.0 169 163 96.4 5 3.0 1 0.6 169
Total 1214 96.0 2 0.2 49 3.9 1265 1257 99.3 0 0.0 9 0.7 1266 1247 98.7 15 1.2 2 0.2 1264
Chloramphenicol Tetracycline SXT 2
Year S (n) S (%) I (n) I (%) R (n) R (%) n S (n) S (%) I (n) I (%) R (n) R (%) n S (n) S (%) I (n) I (%) R (n) R (%) n
2003 68 98.6 0 0.0 1 1.4 69 60 84.5 0 0.0 11 15.5 71 69 100.0 0 0.0 0 0.0 69
2004 159 100.0 0 0.0 0 0.0 159 147 92.5 0 0.0 12 7.5 159 158 100.0 0 0.0 0 0.0 158
2005 88 98.9 0 0.0 1 1.1 89 77 86.5 0 0.0 12 13.5 89 89 100.0 0 0.0 0 0.0 89
2006 88 100.0 0 0.0 0 0.0 88 80 90.9 0 0.0 8 9.1 88 87 98,9 0 0.0 1 1.1 88
2007 86 100.0 0 0.0 0 0.0 86 78 91.8 0 0.0 7 8.2 85 83 100.0 0 0.0 0 0.0 83
2008 106 100.0 0 0.0 0 0.0 106 97 90.7 0 0.0 10 9.3 107 103 100.0 0 0.0 0 0.0 103
2009 116 100.0 0 0.0 0 0.0 116 101 87.1 0 0.0 15 12.9 116 114 98,3 1 0.9 1 0.9 116
2010 129 99.2 0 0.0 1 0.8 130 122 93.8 1 0.8 7 5.4 130 130 100.0 0 0.0 0 0.0 130
2011 120 100.0 0 0.0 0 0.0 120 108 90.0 0 0.0 12 10.0 120 119 99.2 1 0.8 0 0.0 120
2012 128 97.7 2 1.5 1 0.8 131 120 91.6 1 0.8 10 7.6 131 118 90.1 8 6.1 5 3.8 131
2013 164 97.0 3 1.8 2 1.2 169 150 88.8 0 0.0 19 11.2 169 160 95.8 3 1.8 4 2.4 167
Total 1252 99.1 5 0.4 6 0.5 1263 1140 90.2 2 0.2 123 9.7 1265 1230 98.1 13 1.0 11 0.9 1254

1Macrolides: Erythromycin or Clarithromycin;

2SXT susceptibility according to the EUCAST breakpoints. Since the MIC testing of the isolates strictly referred to the CLSI recommendations, the EUCAST breakpoints were used for reasons of comparison only.

For some isolates (n = 35) susceptibility testing was not performed for all nine antibiotics.